The role of BCL-2 family proteins in regulating apoptosis and cancer therapy

Frontiers in Oncology, Journal Year: 2022, Volume and Issue: 12

Published: Oct. 12, 2022

Apoptosis, as a very important biological process, is response to developmental cues or cellular stress. Impaired apoptosis plays central role in the development of cancer and also reduces efficacy traditional cytotoxic therapies. Members B-cell lymphoma 2 (BCL-2) protein family have pro- anti-apoptotic activities been studied intensively over past decade for their importance regulating apoptosis, tumorigenesis, responses anticancer therapy. Since inflammatory induced by apoptosis-induced cell death small, at present, drugs targeting has attracted more attention. Consequently, focus this review summarize current research on BCL-2 proteins proteins. Additionally, mechanism was explored. All findings indicate potential therapy cancer.

Language: Английский

---

Current treatments for non-small cell lung cancer

Frontiers in Oncology, Journal Year: 2022, Volume and Issue: 12

Published: Aug. 11, 2022

Despite improved methods of diagnosis and the development different treatments, mortality from lung cancer remains surprisingly high. Non-small cell (NSCLC) accounts for large majority cases. Therefore, it is important to review current treatments NSCLC in clinic preclinic. In this review, we describe, as a guide clinicians, diagnostic therapies (such chemotherapy, chemoradiotherapy, targeted therapy, antiangiogenic immunotherapy, combination therapy) NSCLC.

Language: Английский

---

EGFR is a potential dual molecular target for cancer and Alzheimer’s disease

Frontiers in Pharmacology, Journal Year: 2023, Volume and Issue: 14

Published: Aug. 2, 2023

Many researchers are attempting to identify drugs that can be repurposed as effective therapies for Alzheimer’s disease (AD). Several recent studies have highlighted epidermal growth factor receptor (EGFR) inhibitors approved use anti-cancer potential candidates repurposing AD therapeutics. In cancer, EGFR target cell proliferation and angiogenesis, in mouse models shown attenuate amyloid-beta (Aβ) pathology improve cognitive function. this review, we discuss the different functions of cancer a dual molecular diseases. addition, describe effects tyrosine kinase (TKIs) on their prospects therapeutic interventions AD. By summarizing physiological AD, review emphasizes significance an important these

Language: Английский

---

Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 161, P. 114452 - 114452

Published: March 3, 2023

Non-small cell lung carcinoma (NSCLC) is the most common malignancy worldwide. The signaling cascades are stimulated via genetic modifications in upstream molecules, which affect apoptotic, proliferative, and differentiation pathways. Dysregulation of these causes cancer-initiating proliferation, cancer development, drug resistance. Numerous efforts treatment NSCLC have been undertaken past few decades, enhancing our understanding mechanisms development moving forward to develop effective therapeutic approaches. Modifications transcription factors connected pathways utilized new options for NSCLC. Developing designed inhibitors targeting specific cellular tumor progression has recommended management This comprehensive review provided deeper mechanistic insights into molecular mechanism action various molecules their clinical

Language: Английский

---

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review

Frontiers in Pharmacology, Journal Year: 2023, Volume and Issue: 14

Published: Nov. 6, 2023

Abnormal cellular apoptosis plays a pivotal role in the pathogenesis of Multiple Myeloma (MM). Over years, BCL-2, crucial anti-apoptotic protein, has garnered significant attention MM therapeutic research. Venetoclax (VTC), small-molecule targeted agent, effectively inhibits promoting programmed death cancerous cells. While VTC been employed to treat various hematological malignancies, its particular efficacy showcased potential for broader clinical applications. In this review, we delve into intricacies how modulates cells by targeting BCL-2 and overarching influence protein family regulation. Our findings highlight nuanced interplay between VTC, MM, offering insights that may pave way optimizing strategies. Through comprehensive analysis, aim lay solid groundwork future explorations VTC’s applications profound effects on apoptosis.

Language: Английский

---

Biochemical features and therapeutic potential of α-Mangostin: Mechanism of action, medicinal values, and health benefits

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 163, P. 114710 - 114710

Published: May 3, 2023

α-Mangostin (α-MG) is a natural xanthone obtained from the pericarps of mangosteen. It exhibits excellent potential, including anti-cancer, neuroprotective, antimicrobial, antioxidant, and anti-inflammatory properties, induces apoptosis. α-MG controls cell proliferation by modulating signaling molecules, thus implicated in cancer therapy. possesses incredible pharmacological features modulates crucial cellular molecular factors. Due to its lesser water solubility pitiable target selectivity, has limited clinical application. As known gained significant attention scientific community, increasing interest extensive technical biomedical applications. Nanoparticle-based drug delivery systems were designed improve efficiency α-MG. This review focused on recent developments therapeutic potential managing neurological diseases, with special focus mechanism action. In addition, we highlighted biochemical features, metabolism, functions, anti-inflammatory, antioxidant effects pre-clinical applications

Language: Английский

---

Receptor-Targeted Nanomedicine for Cancer Therapy

Receptors, Journal Year: 2024, Volume and Issue: 3(3), P. 323 - 361

Published: July 3, 2024

Receptor-targeted drug delivery has been extensively explored for active targeting of therapeutic moiety in cancer treatment. In this review, we discuss the receptors that are overexpressed on tumor cells and have potential to be targeted by nanocarrier systems We also highlight different types ligands researchers explored. Our discussion covers various modalities, including small molecules, aptamers, peptides, antibodies, cell-based strategies, focuses clinical developments. Additionally, article highlights challenges arise during translation nanocarrier-based strategies. It provides future directions improving research area clinically translatable cancer-targeted therapy improve treatment efficacy while minimizing toxicity.

Language: Английский

---

Epigallocatechin gallate modulates ferroptosis through downregulation of tsRNA-13502 in non-small cell lung cancer

Cancer Cell International, Journal Year: 2024, Volume and Issue: 24(1)

Published: June 5, 2024

Abstract Ferroptosis, an iron-dependent regulated cell death mechanism, holds significant promise as a therapeutic strategy in oncology. In the current study, we explored regulatory effects of epigallocatechin gallate (EGCG), prominent polyphenol green tea, on ferroptosis and its potential implications for non-small lung cancer (NSCLC). Treatment NSCLC lines with varying concentrations EGCG resulted notable suppression proliferation, evidenced by reduction Ki67 immunofluorescence staining. Western blot analyses demonstrated that treatment led to decrease expression glutathione peroxidase 4 (GPX4) solute carrier family 7 member 11 (SLC7A11) while increasing levels acyl-CoA synthetase long-chain (ACSL4). These molecular changes were accompanied increase intracellular iron, malondialdehyde (MDA), reactive oxygen species (ROS), alongside ultrastructural alterations characteristic ferroptosis. Through small RNA sequencing RT-qPCR, transfer RNA-derived 13502 (tsRNA-13502) was identified target action, being upregulated tissues compared adjacent non-tumorous tissues. found modulate pathway downregulating tsRNA-13502 altering key regulators (GPX4/SLC7A11 ACSL4), thereby promoting accumulation MDA, ROS, ultimately inducing cells. This study elucidates EGCG’s multifaceted mechanisms underscoring modulation viable approach enhancing outcomes.

Language: Английский

---

Folic acid-functionalized PEGylated niosomes co-encapsulated cisplatin and doxoribicin exhibit enhanced anticancer efficacy

Cancer Nanotechnology, Journal Year: 2024, Volume and Issue: 15(1)

Published: Feb. 13, 2024

Abstract The medical field is faced with the difficult task of developing a new approach to curing cancer, which prevalent in organs such as breast and ovaries has high mortality rate. Since chemotherapy conventional method treatment, efforts are being made improve it help patients function better. Fortunately, use nanocarriers their remarkable ability manage direct drug delivery, progress cancer treatment. In addition, folic acid-coated offer several advantages including improved stability, bioavailability, targeted delivery solubility. These properties make them promising tools for improving treatment efficacy. This research focused on investigating stability specific niosomal formulation (consisting Span 60 cholesterol) under different temperature conditions (4 25 ℃) 2 months. release rate was evaluated. results showed that size polydispersity index increased significantly studies, but entrapment efficiency% decreased dramatically over time. encapsulation drugs formulations resulted stable slow release. cytotoxicity evaluation containing doxorubicin cisplatin show significant inhibitory effect both ovarian cell lines (IC 50 DOX–CIS–Nio@PEG–FA 6.11 17.87 µg/mL A2780 MCF-7, respectively). Niosomes loaded combination two were found affect gene expression tested. They BCl2, VEGF, CCND1, HER2 genes while increasing BAX gene. Flow cytometry indicated niosomes apoptosis compared mixture. ROS cycle arrest, confirm inhibition cells destruction presence synthesized noisome comparison free drugs. potential this novel delivering lies combine treatments target multiple cancers simultaneously. Such allow co-delivery cells, thereby efficacy through synergistic effects between Graphical

Language: Английский

---

Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast Cancer

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(3), P. 1078 - 1078

Published: Jan. 26, 2025

Triple-negative breast cancer (TNBC) represents the most aggressive carcinoma subtype lacking efficient therapeutic options. A promising approach in treatment is pharmacological inhibition of murine double minute 2 (MDM2)-p53 interaction inducing apoptosis p53 wild-type tumors. However, role MDM2 TNBC with primarily mutant not well understood. We here selected clinical-stage inhibitors Idasanutlin and Milademetan investigated their anti-tumoral effects TNBC. When we analyzed anti-tumor activity cell lines MDA-MB-231, MDA-MB-436, MDA-MB-468, cellular viability was efficiently reduced, half maximal inhibitory concentration (IC50) values ranging between 2.00 7.62 µM being up to 11-fold lower compared well-characterized non-clinical-stage inhibitor Nutlin-3a. Furthermore, caspase-3/7 induced. Importantly, IC50 for were equally observed HCT116 p53+/+ or p53−/− cells. Finally, significantly higher non-malignant MCF-10A cells than Taken together, show a potent culture models by tumor death via apoptosis. This effect despite an inactivating mutation apparently independent expression. Our data suggest that target should be further evaluated potential application.

Language: Английский

---